Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GlaxoSmithKline ( (GB:GSK) ) just unveiled an update.
GSK has announced the purchase of 230,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on December 12, 2025, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, with the shares being held as treasury shares. Following this purchase, GSK holds a total of 238,856,577 ordinary shares in treasury, representing 5.86% of the voting rights, which may influence shareholder decisions under regulatory guidelines.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £1500.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, support its growth outlook. However, challenges in cash flow and certain market segments warrant cautious optimism.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a leading global healthcare company involved in the pharmaceutical industry, focusing on the development and distribution of medicines, vaccines, and consumer healthcare products.
Average Trading Volume: 8,984,987
Technical Sentiment Signal: Buy
Current Market Cap: £73.63B
See more data about GSK stock on TipRanks’ Stock Analysis page.